L0T Stock Chart & Stats
€63.95
--
Market closed
€63.95
--
Day’s Range― - ―
52-Week Range€50.29 - €76.52
Previous CloseN/A
VolumeN/A
Average Volume (3M)164.00
Market Cap
€25.78B
Enterprise Value€36.11B
Total Cash (Recent Filing)€2.29B
Total Debt (Recent Filing)€10.58B
Price to Earnings (P/E)19.6
Beta1.04
Next Earnings
Jul 29, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.30
Shares Outstanding454,891,780
10 Day Avg. Volume62
30 Day Avg. Volume164
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€67.89Price Target Upside6.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)4.27
Revenue Forecast (FY)€19.07B
Bulls Say, Bears Say
Bulls Say
Strong Backlog & Order CoverA $21.8B record backlog and 1.07x book-to-bill provide durable revenue visibility across quarters, smoothing capital-equipment cyclicality. This backlog supports predictable service, upgrades and consumable demand, underpinning medium-term revenue and cash flow conversion.
Recurring Services RevenueHigh-margin services growth strengthens recurring revenue mix and margin stability. A larger installed base drives spare parts, maintenance and upgrades, improving cash visibility and defensive resilience through capital spending cycles over the next several years.
Regulatory Wins & Product InnovationRecent product and regulatory milestones (photon-counting CT approvals, MR clearances) accelerate commercialization of differentiated systems. Sustained innovation and clearances expand addressable markets, support premium positioning and foster durable adoption by hospitals and research centers.
Bears Say
Moderate LeverageDebt near parity with equity limits financial flexibility for M&A, R&D spend or cyclical shocks. For a healthcare tech company, elevated leverage raises refinancing and covenant risk and reduces room to opportunistically invest if operating margins soften.
Weaker Recent Cash ConversionA meaningful TTM decline in free cash flow and weaker cash conversion constrains capital allocation choices. Lower FCF reduces capacity for debt paydown, R&D and buybacks, making the company more sensitive to operational headwinds over the medium term.
Margin Pressure From Inflation & Supply IssuesMaterial inflation (~$250M), tariffs and supplier-related quality/recall impacts compress margins and force price/cost actions. Persistent input-cost and tariff uncertainty can depress profitability and delay margin recovery, pressuring free cash flow and returns over multiple quarters.
L0T FAQ
What was Ge Healthcare Technologies Inc.’s price range in the past 12 months?
Ge Healthcare Technologies Inc. lowest stock price was €50.29 and its highest was €76.52 in the past 12 months.
What is Ge Healthcare Technologies Inc.’s market cap?
Ge Healthcare Technologies Inc.’s market cap is €25.78B.
When is Ge Healthcare Technologies Inc.’s upcoming earnings report date?
Ge Healthcare Technologies Inc.’s upcoming earnings report date is Jul 29, 2026 which is in 18 days.
How were Ge Healthcare Technologies Inc.’s earnings last quarter?
Ge Healthcare Technologies Inc. released its earnings results on Apr 29, 2026. The company reported €0.866 earnings per share for the quarter, missing the consensus estimate of €0.914 by -€0.048.
Is Ge Healthcare Technologies Inc. overvalued?
According to Wall Street analysts Ge Healthcare Technologies Inc.’s price is currently Undervalued.
Does Ge Healthcare Technologies Inc. pay dividends?
Ge Healthcare Technologies Inc. does not currently pay dividends.
What is Ge Healthcare Technologies Inc.’s EPS estimate?
Ge Healthcare Technologies Inc.’s EPS estimate is 0.9.
How many shares outstanding does Ge Healthcare Technologies Inc. have?
Ge Healthcare Technologies Inc. has 454,891,780 shares outstanding.
What happened to Ge Healthcare Technologies Inc.’s price movement after its last earnings report?
Ge Healthcare Technologies Inc. reported an EPS of €0.866 in its last earnings report, missing expectations of €0.914. Following the earnings report the stock price went down -15.367%.
Which hedge fund is a major shareholder of Ge Healthcare Technologies Inc.?
Currently, no hedge funds are holding shares in DE:L0T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€67.89 (6.16% Upside)
€67.89 (6.16% Upside)
Blogger Sentiment
Bullish
DE:L0T Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €5.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.16%
12-Months-Change
Fundamentals
Return on Equity
14.77%
Trailing 12-Months
Asset Growth
10.54%
Trailing 12-Months
Company Description
Ge Healthcare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
L0T Company Deck
L0T Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging top-line execution, product/regulatory milestones, a record backlog and strategic progress (Flyrcado ramp, Photonova approvals, Intelerad acquisition, organizational realignment) against meaningful near-term profitability headwinds from supplier issues, tariffs and material inflation (~$250M gross impact). Management maintained revenue guidance but prudently reduced earnings guidance and emphasized mitigation actions whose benefits are weighted to the back half of 2026. The tone was confident on medium-term growth while realistic on near-term margin pressure.View all DE:L0T earnings summariesL0T Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other

L0T Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€67.89
▲(6.16% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Veeva Systems
―
Healthequity
―
Doximity
―
Tempus AI, Inc. Class A
―
Hinge Health, Inc. Class A
―
Options Prices
Currently, No data available
---











